RecruitingNCT06690801

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome


Sponsor

Children's Hospital Los Angeles

Enrollment

1,260 participants

Start Date

Oct 3, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk stratification of mortality in pediatric ARDS 2. To determine if there is heterogeneity in treatment effect for iNO defined by AVDSf 3. To detect the association between AVDSf and microvascular dysfunction trajectory and whether iNO therapy modifies this association This is a prospective, multicenter observational study of 1260 mechanically ventilated children with moderate to severe ARDS. In a subgroup of 450 children with severe ARDS, longitudinal blood samples will be obtained to measure plasma protein markers.


Eligibility

Min Age: 0 YearsMax Age: 21 Years

Inclusion Criteria3

  • Age >37 weeks corrected gestational age to 21 years, including adults lacking the capacity to consent.
  • Within 72 hours of the start of invasive mechanical ventilation and meet the criteria for pediatric ARDS (new infiltrate on chest imaging and a known ARDS risk factor within 7 days of the onset of hypoxemia) and either meet criteria for moderate or severe pediatric ARDS between 4-72 hours of IMV (OI ≥ 8 or OSI ≥ 7.5) OR have an OI ≥ 20 or an OSI ≥ 14 x 15 minutes between 0-4 hours of IMV.
  • Subgroup of children eligible for longituduinal Blood Collection: Children with severe PARDS (OI ≥ 16 or an OSI ≥ 12 between 4-72 hours of IMV) or those with an OI ≥ 20 or an OSI ≥ 14 for 15 minutes between 0-4 hours of IMV will be eligible for collection of longitudinal plasma samples.

Exclusion Criteria9

  • Non-conventional invasive mechanical ventilation (i.e. High Frequency Oscillatory Ventilation, Airway Pressure Release Ventilation) at the time of ICU admission
  • ECMO or iNO (or other inhaled pulmonary vasodilator therapy) at the time of ICU admission
  • Significant lower airways obstruction (examination of ventilator and capnography waveforms by site study or medical team)
  • Air leak >20% (endotracheal tube, tracheostomy tube, or thoracostomy tube)
  • Home Invasive Mechanical Ventilation
  • Cyanotic Congenital Heart Disease
  • Previous enrollment in the DiNO study
  • Do not resuscitate order at the time of pediatric ARDS diagnosis.
  • Blood gas not obtained prior to initiation of ECMO, iNO, or non-conventional ventilation.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(10)

Children's Hospital Los Angeles

Los Angeles, California, United States

Children's Hospital Colorado

Denver, Colorado, United States

Boston Children's Hospital

Boston, Massachusetts, United States

University of Michigan / CS Mott Children's Hospital

Ann Arbor, Michigan, United States

University of Nebraska Medical Center / Children's Hospital and Medical Center

Omaha, Nebraska, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Texas Children's Hospital Baylor College of Medicine

Houston, Texas, United States

American Family Children's Hospital / University of Wisconsin-Madison

Madison, Wisconsin, United States

Children's Hospital of Wisconsin / Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06690801


Related Trials